Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration

Clinical Science

Volumn 99, Issue 4, 2000, Pages 331-341

  Fabiani, M E ^a   Dinh, D T ^a   Nassis, L ^a   Casley, D J ^a   Johnston, C I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin; Angiotensin II antagonists; Angiotensin receptors; AT1 receptor antagonists; AT1 receptors; Irbesartan; Losartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IODINE 125; IRBESARTAN; LOSARTAN; RADIOLIGAND;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; FEEDING; GLOMERULUS; IC 50; KIDNEY; KIDNEY MEDULLA; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING;

EID: 0033787257     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0990331     Document Type: Article

References (50)

1. Renin-angiotensin system: Biochemistry and mechanisms of action
2. Biochemistry and pharmacology of the renin-angiotensin system
3. Angiotensin-II-receptors: New targets for antihypertensive therapy
4. RAA system and cardiovascular control in normal subjects, hypertensives and patients with congestive heart failure
5. The importance of the renin-angiotensin system in cardiovascular disease
6. Angiotensin receptor subtypes: Novel targets for cardiovascular therapy
7. 1-receptor blockers
8. 2 receptor
9. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system
10. Angiotensin-converting enzyme inhibitors
11. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection
12. Angiotensin-converting enzyme: Basic properties, distribution and functional role
13. Cough and angioneurotic edema associated with angiotensn-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
14. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases
15. Dual pathway for angiotensin II formation in human internal mammary arteries
16. Angiotensin converting enzyme inhibitors
17. Angiotensin II receptor antagonists in hypertension
18. Spectrum of use for the angiotensin receptor blocking drugs
19. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
20. Clinical overview of irbesartan: A new angiotensin II receptor antagonist
21. A look through the new therapeutic window: Irbesartan
22. The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations
23. Discovery of losartan, the first angiotensin II receptor antagonist
24. Angiotensin receptor antagonists: Focus on losartan
25. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent
26. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent
27. 1 subtype angiotensin II receptor antagonist
28. 1 receptor antagonist, on human vascular smooth muscle cells in vitro
29. Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues
30. Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: Potential mechanisms of action
31. Angiotensin II receptors in the kidney
32. Localization and properties of angiotensin II receptors in rat kidney
33. Angiotensin II receptors in the kidney
34. 1 angiotensin II receptors in rat kidney
35. 1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography
36. Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one-clip Goldblatt hypertensive rats
37. Evaluation of renin and angiotensin assays and their clinical applications
38. Measurement of angiotensin converting enzyme inhibitors in serum by radioinhibitor binding displacement assay
39. 2-receptors in rat kidney
40. Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor
41. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
42. Application of Bradford's protein assay to adrenal gland subcellular fractions
43. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers
44. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
45. Human pharmacokinetic/pharmacodynamic profile of irbesartan: A new potent angiotensin II receptor antagonist
46. A review of the new angiotensin II receptor antagonist irbesartan
47. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators
48. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators
49. Erratum
50. 1 receptor antagonists